Osteoarthritis of the KneePhase 3MOVE-OKNCT05035810
A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee Marching On for Veterans With Osteoarthritis of the Knee
A Phase 3 study testing Social Incentives and Gamification to Promote Exercise, Corticosteroid Injection given in A-B order and No Social Incentive applied in people with Osteoarthritis of the Knee, run by VA Office of Research and Development at 4 sites in United States.
Trial summary
Knee osteoarthritis (KOA) is one of the most common and disabling conditions among Veterans. Management of KOA is challenging as there are few effective treatments other than joint replacement. Importantly, low levels of physical activity in patients with knee problems might worsen pain and disability. Read more about this study
- Who is it for?
- Ages 40 to 80 years
- Conditions the study is for
- Osteoarthritis of the Knee
- What is being tested?
- Social Incentives and Gamification to Promote Exercise, Corticosteroid Injection given in A-B order and No Social Incentive applied
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 221 participants
- Where
- 4 sitesUnited States
- Study dates
- 14 Mar 2022to 31 Dec 2025
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Veterans in VA Rheumatology or Orthopedic clinics
- Chronic knee osteoarthritis
- Indication for joint injection
- Previous joint injections for palliation
- Patient expresses interest in increasing their physical activity
- Patient is able to walk 1/2 mile per day
Who cannot join
- Intra-articular hardware or other contraindication to joint injection
- Lack of smart phone
- Acute exacerbation of osteoarthritis or knee pain
- Comorbid condition that precludes safe exercise
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska, 68105-1873
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, 19104-4551
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, 98108
Washington DC VA Medical Center, Washington, DC
Washington D.C., District of Columbia, 20422
About this study
Official title: A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee
Knee osteoarthritis (KOA) is one of the most common and disabling conditions among Veterans. Management of KOA is challenging as there are few effective treatments other than joint replacement. Importantly, low levels of physical activity in patients with knee problems might worsen pain and disability. This study aims to determine the feasibility of using methods to change behavior that use social incentives and promote physical activity through playing games and interacting with a web-based platform. The study will also evaluate an important and widely used treatment, namely corticosteroid injections. Participants will be randomized into one of 4 arms and will receive a different combination of social incentives and injections. The study will evaluate which approach is most effective at promoting physical activity and reducing pain and disability.
Read the detailed description
Knee osteoarthritis (KOA) is one of the most prevalent and disabling conditions among Veterans and accounts for high morbidity and high costs for the VA. Management of KOA is challenging as there are few consistently effective treatments other than joint replacement. Importantly, chronic reductions in physical activity in patients with KOA may worsen pain, physical function, and exacerbate the metabolic consequences of obesity. Moreover, the greater mortality observed in symptomatic knee OA populations is likely mediated through its effect on physical activity. The current proposal aims to derive preliminary data to support a large pragmatic trial testing the impact of interventions geared towards improving physical activity and function in KOA patients.
Promoting physical activity has been shown to be helpful in reducing pain and improving function in KOA and other groups. However, promoting behavioral change in the arthritis population is a significant challenge. The group has shown that social incentives [and gamification] derived from concepts from the field of behavioral economics to promote behavioral change and increase physical activity can be both practical and effective in other settings. The investigators' group is studying incentives in patients with inflammatory arthritis with the goal of addressing fatigue, pain, and deficits in physical function. The incentivization of physical activity using this approach represents a novel intervention for the managing symptoms of KOA and to improving overall health.
Analgesic therapies can help KOA patients participate in exercise therapy. However, whether corticosteroid injections, a commonly used medical therapy for KOA pain, has a positive impact of physical activity is unknown and is an additional important question addressed by the current proposal. Despite widespread use, definitive data demonstrating a consistent benefit of corticosteroids are lacking. A large randomized trial recently tested the effects of repeated corticosteroids injections every 3 months for a period of 2 years on patient reported pain as well as progression of disease measured by magnetic resonance imaging (MRI). This study demonstrated no improvement in pain compared to saline injections. In addition, a small but statistically significant decline in cartilage thickness on MRI was observed, raising a concern for side effects. These recent data might suggest that corticosteroid injections result in more harm than good, and may discourage providers from performing this intervention. However, there are critical weaknesses to this study. Pain and function were only assessed at 3-month intervals, while previous trials have suggested that peak benefit is expected at 4-8 weeks. Moreover, the clinical and biologic significance decrease in cartilage thickness is unclear.
The investigators propose to fill these important knowledge gaps with an innovative and efficient pragmatic clinical trial with a factorial and crossover design. A large and definitive practical trial would lead to better understanding of the clinical effectiveness of these interventions, the meaningfulness of their combined impact, and the subgroups that are most likely to derive benefit. This clinical trial will leverage unique resources available through the Penn Center for Innovation to better capture important patient-reported outcomes in real-time through a web-based platform. The study will also test the feasibility of a crossover and factorial design to improve efficiency and reduce confounding. Each patient will receive each intervention (saline, corticosteroids) in random order over 1 year. A factorial design will be employed and will randomize participants to receive social incentives with gamification to promote increases in their physical activity. To accomplish these aims, the investigators will utilize innovative mobile applications for smart phones and wearable activity trackers through the Way-to-Health platform and assess, in real time, the impact of the intervention on patient-reported function and pain as well as physical activity. The technology will allow for the recording of outcomes as they occur, between clinic visits, thereby avoiding information bias due to poor recall. It will also provide real-time assessment of symptoms, providing granular assessments of response over time.
Aim 1: To determine whether an incentive based on behaviorally-enhanced gamification can improve physical activity among patients with KOA and reduce self-reported pain and disability. The intervention will result in sustained improvements in average daily step counts over 10 months.
Aim 2: To determine if corticosteroid injections can reduce pain and disability in patients with KOA when compared to lidocaine only. Participants will report improvements in self-reported pain and disability, and improvements in quality of life.
- Conditions
- Osteoarthritis of the Knee
- Being tested
- Social Incentives and Gamification to Promote Exercise, Corticosteroid Injection given in A-B order, No Social Incentive applied, Procedure: Corticosteroid Injection given in B-A order
- Keywords
- corticosteroid injection, physical activity, pain, disability, behavioral incentives, Osteoarthritis, Osteoarthritis, Knee, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
- Medical subject headings
- Osteoarthritis, Knee, Motor Activity, Pain, Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Social Incentives and Gamification to Promote ExerciseBehavioural
The intervention will provide social incentives and gamification to promote physical activity.
Corticosteroid Injection given in A-B orderDrug
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
No Social Incentive appliedBehavioural
No social incentive will be applied
Procedure: Corticosteroid Injection given in B-A orderDrug
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
| Study group | Role | What they receive |
|---|---|---|
| Social Incentives and Gamification, Corticosteroid AB | Experimental | Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
The participants will receive injections in A-B order (corticosteroids, then lidocaine only) Receives: Behavioral: Social Incentives and Gamification to Promote Exercise; Drug: Corticosteroid Injection given in A-B order |
| No Incentive, Corticosteroid AB | Active comparator | Participants will only receive reminders to sync their activity monitor.
The participants will receive injections in A-B order (corticosteroids, then lidocaine only) Receives: Drug: Corticosteroid Injection given in A-B order; Behavioral: No Social Incentive applied |
| Social Incentives and Gamification, Corticosteroid BA | Experimental | Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
The participants will receive injections in B-A order (lidocaine only, then corticosteroids) Receives: Behavioral: Social Incentives and Gamification to Promote Exercise; Drug: Procedure: Corticosteroid Injection given in B-A order |
| No Incentive, Corticosteroid BA | Active comparator | Participants will only receive reminders to sync their activity monitor.
The participants will receive injections in B-A order (lidocaine only, then corticosteroids) Receives: Behavioral: No Social Incentive applied; Drug: Procedure: Corticosteroid Injection given in B-A order |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change from baseline in weekly average steps per day
Steps measured by a wearable activity monitor
Measured: Measured weekly over 10 months (for exercise intervention)
Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)
KOOS assessed by survey at 2 week intervals. KOOS scores range from 0 to 100 with 0 representing worse knee problems and 100 representing no knee problems.
Measured: Measured bi-weekly over the first 3 months (for injection intervention)
Secondary outcomes (3)
Change in PROMIS pain intensity score
Assessed by survey at 2 week intervals. Scores range from 3-15 and are converted to T-Scores. A high score represents greater pain.
Measured: Measured bi-weekly over 3-10 months (3 for injection intervention and 10 for exercise intervention)
Change in PROMIS Fatigue
Assessed by survey at 4 week intervals
Measured: Measured every 4 weeks over 3-10 months (3 for injection intervention and 10 for exercise intervention)
Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS)
KOOS assessed by survey at 2 week intervals. KOOS scores range from 0 to 100 with 0 representing worse knee problems and 100 representing no knee problems.
Measured: Measured bi-weekly over 10 months (for exercise intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2021
- Study start14 Mar 2022
- Primary completion30 Nov 2024
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Osteoarthritis of the KneeStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- Participants are randomized with a software application to receive social incentives to promote physical activity. They will also be randomized to receive corticosteroid injections in a crossover design.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 221 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Joshua F. Baker, MD MSCE, Principal investigator, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05035810
- Sponsor's protocol ID
- F3644-R
- Other IDs
- RX003644-01A1
- Acronym
- MOVE-OK
- Status last verified
- Mar 2025
- First submitted
- 26 Aug 2021
- Last updated
- 20 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Data sets will be available through a formal request process through the PI and co-investigators. Data will not be shared without the approval of CVCVAMC IRB. When shared, data will be de-identified and anonymized.
Publications
Leach W, Doherty C, Olave M, England BR, Wysham K, Kerr G, Quinones M, Ogdie A, White D, Neogi T, Scanzello CR, Baker JF. Protocol for a multi-center randomized controlled trial to evaluate the benefits of exercise incentives and corticosteroid injections in osteoarthritis of the knee (MOVE-OK). Trials. 2022 Jul 27;23(1):604. doi: 10.1186/s13063-022-06529-w.
PubMed 35897080Gillcrist RL, Doherty CR, Olave M, Bonilla J, England BR, Wysham K, Quinones M, Scanzello CR, Ogdie A, White DK, Neogi T, Baker JF. A Remote Behaviorally Designed Intervention to Promote Physical Activity in Patients With Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial. J Clin Rheumatol. 2024 Dec 1;30(8):336-339. doi: 10.1097/RHU.0000000000002148. Epub 2024 Oct 16.
PubMed 39412672
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee
- ClinicalTrials.gov ID
- NCT05035810
- Acronym / sponsor ID
- MOVE-OK / F3644-R
- Conditions
- Osteoarthritis of the Knee
- Keywords
- corticosteroid injection, physical activity, pain, disability, behavioral incentives, Osteoarthritis, Osteoarthritis, Knee, Arthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 221 participants (actual)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 14 Mar 2022 (actual)
- Primary completion
- 30 Nov 2024 (actual)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 5 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Knee osteoarthritis (KOA) is one of the most common and disabling conditions among Veterans. Management of KOA is challenging as there are few effective treatments other than joint replacement. Importantly, low levels of physical activity in patients with knee problems might worsen pain and disability. This study aims to determine the feasibility of using methods to change behavior that use social incentives and promote physical activity through playing games and interacting with a web-based platform. The study will also evaluate an important and widely used treatment, namely corticosteroid injections. Participants will be randomized into one of 4 arms and will receive a different combination of social incentives and injections. The study will evaluate which approach is most effective at promoting physical activity and reducing pain and disability.
Detailed description
Knee osteoarthritis (KOA) is one of the most prevalent and disabling conditions among Veterans and accounts for high morbidity and high costs for the VA. Management of KOA is challenging as there are few consistently effective treatments other than joint replacement. Importantly, chronic reductions in physical activity in patients with KOA may worsen pain, physical function, and exacerbate the metabolic consequences of obesity. Moreover, the greater mortality observed in symptomatic knee OA populations is likely mediated through its effect on physical activity. The current proposal aims to derive preliminary data to support a large pragmatic trial testing the impact of interventions geared towards improving physical activity and function in KOA patients.
Promoting physical activity has been shown to be helpful in reducing pain and improving function in KOA and other groups. However, promoting behavioral change in the arthritis population is a significant challenge. The group has shown that social incentives [and gamification] derived from concepts from the field of behavioral economics to promote behavioral change and increase physical activity can be both practical and effective in other settings. The investigators' group is studying incentives in patients with inflammatory arthritis with the goal of addressing fatigue, pain, and deficits in physical function. The incentivization of physical activity using this approach represents a novel intervention for the managing symptoms of KOA and to improving overall health.
Analgesic therapies can help KOA patients participate in exercise therapy. However, whether corticosteroid injections, a commonly used medical therapy for KOA pain, has a positive impact of physical activity is unknown and is an additional important question addressed by the current proposal. Despite widespread use, definitive data demonstrating a consistent benefit of corticosteroids are lacking. A large randomized trial recently tested the effects of repeated corticosteroids injections every 3 months for a period of 2 years on patient reported pain as well as progression of disease measured by magnetic resonance imaging (MRI). This study demonstrated no improvement in pain compared to saline injections. In addition, a small but statistically significant decline in cartilage thickness on MRI was observed, raising a concern for side effects. These recent data might suggest that corticosteroid injections result in more harm than good, and may discourage providers from performing this intervention. However, there are critical weaknesses to this study. Pain and function were only assessed at 3-month intervals, while previous trials have suggested that peak benefit is expected at 4-8 weeks. Moreover, the clinical and biologic significance decrease in cartilage thickness is unclear.
The investigators propose to fill these important knowledge gaps with an innovative and efficient pragmatic clinical trial with a factorial and crossover design. A large and definitive practical trial would lead to better understanding of the clinical effectiveness of these interventions, the meaningfulness of their combined impact, and the subgroups that are most likely to derive benefit. This clinical trial will leverage unique resources available through the Penn Center for Innovation to better capture important patient-reported outcomes in real-time through a web-based platform. The study will also test the feasibility of a crossover and factorial design to improve efficiency and reduce confounding. Each patient will receive each intervention (saline, corticosteroids) in random order over 1 year. A factorial design will be employed and will randomize participants to receive social incentives with gamification to promote increases in their physical activity. To accomplish these aims, the investigators will utilize innovative mobile applications for smart phones and wearable activity trackers through the Way-to-Health platform and assess, in real time, the impact of the intervention on patient-reported function and pain as well as physical activity. The technology will allow for the recording of outcomes as they occur, between clinic visits, thereby avoiding information bias due to poor recall. It will also provide real-time assessment of symptoms, providing granular assessments of response over time.
Aim 1: To determine whether an incentive based on behaviorally-enhanced gamification can improve physical activity among patients with KOA and reduce self-reported pain and disability. The intervention will result in sustained improvements in average daily step counts over 10 months.
Aim 2: To determine if corticosteroid injections can reduce pain and disability in patients with KOA when compared to lidocaine only. Participants will report improvements in self-reported pain and disability, and improvements in quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
- Model description
- Participants are randomized with a software application to receive social incentives to promote physical activity. They will also be randomized to receive corticosteroid injections in a crossover design.
| Arm | Type | Receives |
|---|---|---|
| Social Incentives and Gamification, Corticosteroid AB | Experimental | Behavioral: Social Incentives and Gamification to Promote Exercise, Drug: Corticosteroid Injection given in A-B orderParticipants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals. The participants will receive injections in A-B order (corticosteroids, then lidocaine only) |
| No Incentive, Corticosteroid AB | Active comparator | Drug: Corticosteroid Injection given in A-B order, Behavioral: No Social Incentive appliedParticipants will only receive reminders to sync their activity monitor. The participants will receive injections in A-B order (corticosteroids, then lidocaine only) |
| Social Incentives and Gamification, Corticosteroid BA | Experimental | Behavioral: Social Incentives and Gamification to Promote Exercise, Drug: Procedure: Corticosteroid Injection given in B-A orderParticipants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals. The participants will receive injections in B-A order (lidocaine only, then corticosteroids) |
| No Incentive, Corticosteroid BA | Active comparator | Behavioral: No Social Incentive applied, Drug: Procedure: Corticosteroid Injection given in B-A orderParticipants will only receive reminders to sync their activity monitor. The participants will receive injections in B-A order (lidocaine only, then corticosteroids) |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Veterans in VA Rheumatology or Orthopedic clinics
- Chronic knee osteoarthritis
- Indication for joint injection
- Previous joint injections for palliation
- Patient expresses interest in increasing their physical activity
Key exclusion criteria (4 listed)
- Intra-articular hardware or other contraindication to joint injection
- Lack of smart phone
- Acute exacerbation of osteoarthritis or knee pain
- Comorbid condition that precludes safe exercise
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Social Incentives and Gamification to Promote ExerciseThe intervention will provide social incentives and gamification to promote physical activity. | Behavioural | Social Incentives and Gamification, Corticosteroid AB, Social Incentives and Gamification, Corticosteroid BA |
| Corticosteroid Injection given in A-B orderThe study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order. | Drug | No Incentive, Corticosteroid AB, Social Incentives and Gamification, Corticosteroid AB |
| No Social Incentive appliedNo social incentive will be applied | Behavioural | No Incentive, Corticosteroid AB, No Incentive, Corticosteroid BA |
| Procedure: Corticosteroid Injection given in B-A orderThe study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order. | Drug | No Incentive, Corticosteroid BA, Social Incentives and Gamification, Corticosteroid BA |
Primary outcome
Percent change from baseline in weekly average steps per day
Time frame: Measured weekly over 10 months (for exercise intervention)
Steps measured by a wearable activity monitor
Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time frame: Measured bi-weekly over the first 3 months (for injection intervention)
KOOS assessed by survey at 2 week intervals. KOOS scores range from 0 to 100 with 0 representing worse knee problems and 100 representing no knee problems.
3 secondary outcomes
Change in PROMIS pain intensity score
Time frame: Measured bi-weekly over 3-10 months (3 for injection intervention and 10 for exercise intervention)
Change in PROMIS Fatigue
Time frame: Measured every 4 weeks over 3-10 months (3 for injection intervention and 10 for exercise intervention)
Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS)
Time frame: Measured bi-weekly over 10 months (for exercise intervention)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2025.
- Background: PubMed 35897080Leach W, Doherty C, Olave M, England BR, Wysham K, Kerr G, Quinones M, Ogdie A, White D, Neogi T, Scanzello CR, Baker JF. Protocol for a multi-center randomized controlled trial to evaluate the benefits of exercise incentives and corticosteroid injections in osteoarthritis of the knee (MOVE-OK). Trials. 2022 Jul 27;23(1):604. doi: 10.1186/s13063-022-06529-w.
- Derived from this study: PubMed 39412672Gillcrist RL, Doherty CR, Olave M, Bonilla J, England BR, Wysham K, Quinones M, Scanzello CR, Ogdie A, White DK, Neogi T, Baker JF. A Remote Behaviorally Designed Intervention to Promote Physical Activity in Patients With Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial. J Clin Rheumatol. 2024 Dec 1;30(8):336-339. doi: 10.1097/RHU.0000000000002148. Epub 2024 Oct 16.
- Individual participant dataSharing planned: No. Data sets will be available through a formal request process through the PI and co-investigators. Data will not be shared without the approval of CVCVAMC IRB. When shared, data will be de-identified and anonymized.
Related trials for Osteoarthritis of the Knee
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joshua F. Baker, MD MSCE principal investigator
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Social Incentives and Gamification to Promote Exercise, Corticosteroid Injection given in A-B order and No Social Incentive applied in people with Osteoarthritis of the Knee, run by VA Office of Research and Development at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change from baseline in weekly average steps per day (time frame: Measured weekly over 10 months (for exercise intervention)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05035810, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2025.